Stock Analysis

Corbion Full Year 2024 Earnings: Beats Expectations

ENXTAM:CRBN
Source: Shutterstock

Corbion (AMS:CRBN) Full Year 2024 Results

Key Financial Results

  • Revenue: €1.29b (up 1.9% from FY 2023).
  • Net income: €45.9m (up 6.5% from FY 2023).
  • Profit margin: 3.6% (up from 3.4% in FY 2023). The increase in margin was driven by higher revenue.
  • EPS: €0.79 (up from €0.73 in FY 2023).
revenue-and-expenses-breakdown
ENXTAM:CRBN Revenue and Expenses Breakdown March 22nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Corbion Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates significantly.

The primary driver behind last 12 months revenue was the Functional Ingredients & Solutions segment contributing a total revenue of €997.9m (77% of total revenue). Notably, cost of sales worth €968.5m amounted to 75% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to €110.0m (40% of total expenses). Explore how CRBN's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Europe.

Performance of the market in the Netherlands.

The company's shares are down 3.0% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Corbion you should know about.

If you're looking to trade Corbion, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Sponsored Content

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ENXTAM:CRBN

Corbion

Provides lactic acid and lactic acid derivatives, food preservation solutions, functional blends, and algae ingredients in the Netherlands, the United States, Asia, rest of North Americas, the rest of Europe, the Middle East, and Africa.

Proven track record with adequate balance sheet and pays a dividend.